Bortezomib upregulated DR5 but not DR4 receptors cell surface expression in NSCLC cell lines increasing the cell death at the same level with both DR4 and DR5 agonistic antibodies [10]. The gene discussed is TNFRSF10B; the disease is non-small cell lung carcinoma.